Could a new pill help Parkinson's patients think more clearly?

NCT ID NCT04476017

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small study tested an experimental drug called SAGE-718 in 18 people with Parkinson's disease who also had mild thinking and memory problems. The main goal was to see if the drug was safe and tolerable. Researchers also looked at whether it might help with thinking, mood, and movement symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-718 (oral tablets)
What this could lead to: If successful, this could point toward a treatment to ease thinking and memory problems in people with Parkinson's disease.
What could go wrong: This was a very small, early-phase study with only 18 participants, so results may not apply broadly. The drug's effectiveness is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE DYSFUNCTION PARKINSON DISEASE

Contacts and locations

Locations

Sage Investigational Site

Long Beach, California, 90806, United States
Sage Investigational Site

Port Charlotte, Florida, 33980, United States
Sage Investigational Site

West Palm Beach, Florida, 33407, United States
Sage Investigational Site

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.